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Abstract
Deep subcortical lesions (DSCL) of the brain, are present in ~60% of the ageing population,
and are linked to cognitive decline and depression. DSCL are associated with demyelin-
ation, blood brain barrier (BBB) dysfunction, and microgliosis. Microglia are the main
immune cell of the brain. Under physiological conditions microglia have a ramified morphol-
ogy, and react to pathology with a change to a more rounded morphology as well as showing
protein expression alterations. This study builds on previous characterisations of DSCL and
radiologically ‘normal-appearing’ white matter (NAWM) by performing a detailed characteri-
sation of a range of microglial markers in addition to markers of vascular integrity. The Cog-
nitive Function and Ageing Study (CFAS) provided control white matter (WM), NAWM and
DSCL human post mortem tissue for immunohistochemistry using microglial markers (Iba-
1, CD68 and MHCII), a vascular basement membrane marker (collagen IV) and markers of
BBB integrity (fibrinogen and aquaporin 4). The immunoreactive profile of CD68 increased
in a stepwise manner from control WM to NAWM to DSCL. This correlated with a shift from
small, ramified cells, to larger, more rounded microglia. While there was greater Iba-1 immu-
noreactivity in NAWM compared to controls, in DSCL, Iba-1 levels were reduced to control
levels. A prominent feature of these DSCL was a population of Iba-1-/CD68+ microglia.
There were increases in collagen IV, but no change in BBB integrity. Overall the study
shows significant differences in the immunoreactive profile of microglial markers. Whether
this is a cause or effect of lesion development remains to be elucidated. Identifying microglia
subpopulations based on their morphology and molecular markers may ultimately help deci-
pher their function and role in neurodegeneration. Furthermore, this study demonstrates
that Iba-1 is not a pan-microglial marker, and that a combination of several microglial mark-
ers is required to fully characterise the microglial phenotype.
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Introduction
T2-weighted magnetic resonance image (MRI) white matter hyperintensities are a common
feature of the ageing brain [1]. These white matter lesions (WML) are classified based on their
anatomical location, with periventricular lesions (PVL) found in white matter (WM) next to
ventricles, while deep subcortical lesions (DSCL) occur within the centrum semiovale. DSCL
are found in around 60% of the population over 65 years of age and are linked to progressive
cognitive decline and depression [2]. The definitive cause(s) of WML are, as yet, unknown, yet
there is much evidence to suggest blood brain barrier (BBB) dysfunction [3], axonal damage
[4, 5] and cerebral hypoperfusion [6] contribute to their pathogenesis.
WML are associated with myelin loss, BBB dysfunction, and an increase in reactive glia includ-
ing the presence of swollen, fibrinogen+ clasmatodendritic astrocytes, alongside an increase in
microglial response [7]. Microglia are the main immune cell of the central nervous system (CNS),
capable of expressing a variety of cytokines and chemokines that are responsible for the cell’s func-
tion. In general, microglia are classed as M1, a ‘pro-inflammatory’ phenotype and M2, an ‘anti-
inflammatory’ phenotype, these distinct roles have been investigated and challenged profusely in
the literature and it is apparent that this dichotomy is not as clear-cut as initially suggested [8, 9].
Under physiological conditions microglia appear resting and ramified with extending pro-
cesses constantly sensing the brain environment for any change or pathology that can cause them
to respond in a variety of different ways. Cell morphology alone does not fully indicate microglial
function and it is therefore important to examine a range of microglial markers to gain a better
understanding of these cells in the DSCL and the surrounding WM environment in the ageing
brain [10, 11]. Such studies reveal that the microglial response in both PVL and DSCL differs con-
siderably. PVL contain high levels of activated microglia expressing major histocompatibility
complex class II (MHCII) and the costimulatory molecules B7-2 and CD40, along with minichro-
mosome maintenance protein 2 (MCM-2) suggesting a more immune-activated and prolifer-
ative-permissive environment within PVL [12]. In contrast, DSCL contain low levels of MHCII+
microglia instead, high levels of CD68+ microglia with amoeboid morphology are present. CD68
is a transmembrane glycoprotein protein expressed by human monocytes and tissue macrophages
that indicates phagocytic activity, suggesting that within DSCL phagocytic microglia are likely to
be involved in the removal of degraded myelin [12]. The distinct differences in microglial pheno-
type suggest that the nature of the microglial response differs between DSCL and PVL.
Ionized calcium-binding adaptor molecule 1 (Iba-1), a cytoplasmic protein, is considered a
pan microglial marker [13]. While several studies have demonstrated its expression correlates
with microglial activation and inflammation [10, 14, 15], no studies have determined Iba-1
expression in age-associated WML.
The current study builds on the previous histological characterisation of age-associated
WML and compares the detailed immunoreactive profile of three classic microglial markers,
namely Iba-1, CD68 and MHCII. In addition, this study highlights the correlation between
two independent image analytic methods of quantifying these microglial markers in the well
characterised ageing population-representative Cognitive Function and Ageing Study (CFAS)
neuropathology cohort. Furthermore, the study assesses whether changes in vascular integrity
are associated with changes in microglial responses and the implication this may have for the
pathogenesis of age-associated DSCL.
Materials and methods
Tissue
Human autopsy CNS tissue was obtained from the CFAS neuropathology cohort, a well char-
acterised large-prospective multi-centre, ageing population-representative based UK study
Microglia and white matter lesions
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[16]. Informed written consent was obtained from all participants during life. All CFAS partic-
ipants when approached are assessed for mental capacity by research interviewers who are
fully trained in the mental capacity act. Where it is felt a participant no longer has capacity to
consent for themselves a consultee (nominated by the participants previously), is approached
and asked whether in their opinion the participant would have wished to continue to take part
in the study if they had capacity. Where the consultee agrees that the participant would wish to
continue as part of the study we request the consultee sign a declaration agreeing for the partic-
ipant to continue to take part in the study. For brain donation where someone no longer has
the capacity to consent for themselves we get a signed consultee assent to brain donation
which details how they feel the participant would have wished the brain tissue to be used. The
South Birmingham Research Ethics Committee approved the project (REC Ref: 16/WM/0187;
IRAS Project ID: 19826). Anatomically-defined formalin-fixed post-mortem coronal brain
slices underwent MRI to assess WM pathology and the tissue sampled, as previously described
[1–3]. In brief, blocks were sampled from three coronal slices of approximately 1cm thickness
from the level of: the head of the caudate nucleus (anterior slice); the lateral geniculate nucleus
(middle slice) and tip of occipital horn of the lateral ventricle (posterior slice). The MR images
of each brain slice were rated by two experienced radiologists (blind to clinical status) and
given a score for DSCL using a modified Scheltens’ scale [17]. Using these Scheltens’ scores
and the MRI images, 3 block types were sampled from WM by experienced neuropathologists
for histological analysis, corresponding to the “nested study” design of WML using this tissue
resource [1–3]. Control blocks of WM were taken from cases where all three coronal slices
were scored as 0. DSCL blocks were taken from regions with a score of 5 or greater. NAWM
blocks were taken from lesion free regions of WM in which a DSCL of score 3 or greater was
present elsewhere (Table 1). Each tissue block was then subjected to pathological assessment to
confirm classification as control, NAWM or DSCL.
Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) blocks were sectioned at 5μm, deparaffinised and
subjected to antigen retrieval. Sections were then immunostained for Iba-1, CD68 and MHCII
(microglia), glial fibrillary acidic protein (GFAP, astrocytes), proteolipid protein (PLP, mye-
lin), collagen IV (Coll IV, basal lamina), fibrinogen (a serum protein marker) and aquaporin 4
(AQP4, a water channel marker) using an intelliPATH FLX system (A. Menarini Diagnostics
Ltd, Winnersh, UK). A summary of all the primary antibodies and their conditions of use is
shown in Table 2. IHC was performed using a standard IntelliPATH FLX Polymer Detection
Kit, visualised using diaminobenzidine tetrachloride (DAB) and sections counterstained with
haematoxylin.
Table 1. Age, sex, post mortem delay (PMD) of CFAS brain donors.
Median age (years)
(min-max)
Sex (M/F) PMD (h) (min-max)�
Control
(18 blocks from 18 non-lesional brains)
87 (71–96) 7/11 43 (7–120)
NAWM
(16 blocks from 16 individuals)
86 (73–96) 6/10 48 (25–96)
DSCL
(20 blocks from 20 individuals)
86 (71–101) 10/10 42 (17–164)
�Information not available for 28 individuals.
Key: CFAS, Cognitive Function and Ageing Study; M, male; F, female; NAWM, normal appearing white matter;
DSCL, deep subcortical lesion; h, hours
https://doi.org/10.1371/journal.pone.0210888.t001
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The immunoreactive profile of microglia within the DSCL was further assessed by dual
labelling with Iba-1 and CD68 and was completed manually. Following Iba-1 antibody label-
ling using a standard horse-radish peroxidase avidin-biotin complex (ABC) method with DAB
as substrate (Vector Laboratories, UK) as outline above, Iba-1 stained sections were incubated
with the avidin-biotin blocking kit (Vector Laboratories, UK), and incubated overnight at 4˚C
with anti-CD68, followed by the alkaline-phosphatase-conjugated ABC (Vectastain Elite kit,
Vector Laboratories, UK), developed with alkaline phosphatase substrate (Vector Laboratories,
UK; red) and counterstained with haematoxylin. Additional dual labelling was completed
where Iba-1 stained sections (using a standard ABC-HRP method as earlier) were double
labelled, respectively, with CD68 using Streptavidin Alexa Fluor 555 conjugate (Life Technolo-
gies, UK) at 1:500 dilution in replace of the ABC and DAB substrate. Negative controls con-
sisted of sections incubated with isotype controls or in the absence of primary antibody.
Digital histology and image analysis
Quantitative analysis. All immunostained sections were digitally scanned under a 40x
objective lens using a Nanozoomer XR (Hamamatsu, Photonics Ltd., Hertfordshire, UK). The
final resolution of these images was of 0.23μm/pixel. Scanned sections were stored as Nano-
Zoomer Digital Pathology Image (.ndpi) files, and viewed using NDP.View 2 and analysed in
Visiopharm and/or with an in-house toolbox developed in MATLAB (The Mathworks, Natick,
MA). Additionally a semi-quantitative analysis was completed on the fibrinogen-labelled sec-
tions. WM regions of interest (ROI) were selected based on visually assessing the extent of
microglial activation. In Visiopharm the ROI was depicted through Iba-1 and CD68 immuno-
reactivity (S1A Fig green box). Once the ROI was identified, the same ROI was applied to the
consecutive stained sections in Visiopharm (S1C Fig). For analysis done with the MATLAB
toolbox, a circular ROI was depicted from the central point (red cross) guided from the Visio-
pharm Iba-1-defined ROI (S1B and S1D Fig).
All microglial labelled sections were analysed (Iba-1, CD68 and MHCII) in addition to
GFAP, PLP, Coll IV, fibrinogen, and AQP4-immunolabelled sections with the MATLAB tool-
box. For Iba-1, CD68, MHCII, GFAP, PLP and Coll IV an automatic segmentation algorithm
Table 2. Antibody source, specificity and dilution.
Antibody Isotype Dilution (time, temp) Antigen retrieval method Supplier
Iba-1 Mouse
IgG1κ
1:100 (30 min, RT) or (dual IHC 1hr,
RT)
Menarini Diagnostics, Access Revelation, pH6.4,
PC
Millipore, MABN92
CD68 Mouse IgG3 1:100 (30 min, RT), or (dual IHC o/n,
4˚C)
Menarini Diagnostics, Access Revelation, pH6.4,
PC
Abcam, PG-M1, ab783
MHCII Mouse
IgG1κ
1:50 (30 min, RT) Menarini Diagnostics, Access Revelation, pH6.4,
PC
Dako, M0746
GFAP Rabbit IgG 1:2000 (30 min, RT) Menarini Diagnostics, Access Revelation, pH6.4,
PC
Dako, Z0334
PLP Mouse
IgG2a
1:800 (30 min, RT) Menarini Diagnostics, Access Revelation, pH6.4,
PC
BioRad, MCA839G
Collagen IV
(Coll IV)
Rabbit IgG 1:500 (30 min, RT) Menarini Diagnostics, Access Revelation, pH6.4,
PC
Abcam, ab6586
Fibrinogen Rabbit
Ig fraction
1:1000 (30 min, RT) Menarini Diagnostics, Access Revelation, pH6.4,
PC
Dako, A0080
Aquaporin 4
(AQP4)
Rabbit IgG 1:400 (30 min, RT) Menarini Diagnostics, Access Revelation, pH6.4,
PC
Thermo Fisher Scientific, PA5-
36521
Key: MHCII, major histocompatibility complex II; GFAP, glial fibrillary acidic protein; PLP, Proteolipid protein; PC, pressure cooker.
https://doi.org/10.1371/journal.pone.0210888.t002
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based on [18] was implemented. This generated binary images from the scanned brightfield
colour images, i.e. a value of 1 was assigned to the pixels where the stain of interest was present
and 0 where it was absent. The first step of the segmentations was to apply colour deconvolu-
tion to change the representation of the RGB images to DAB, haematoxylin, and background
channels [19]. Only the DAB intensities were kept, leaving a single-channel image. The second
step was smoothing the image, for which we applied a Gaussian filter (σ = 2 pixels) to the DAB
channel. Finally, we applied a global threshold to the filtered DAB channel to get the seg-
mented binary image [20]. The resultant data was represented as an Area Fraction of staining
ranging from 0–1. Alternatively to segmentation, for fibrinogen and AQP4 staining the per-
centage of stain in the ROI was determined by computing the average intensity of the DAB
channel of such images.
Additionally, using Visiopharm for each section labelled with microglial markers (Iba-1,
CD68 and MHCII), 5 images at 20x magnification (each image area 0.925mm2) were sampled
randomly throughout the WM ROI (total sampled area per section: 4.64mm2) (S2 Fig). All
sampled images were fed into a Linear Bayesian detection algorithm within Visiopharm to
determine the area of positive stain (labelled pixels). An average area fraction across all 5
images was generated for each case. Alternatively, for PLP, fibrinogen and AQP4 labelled sec-
tions the positively labelled structures (labelled pixels) were determined as a percentage of the
total area of the ROI.
For all dual-labelled staining within the DSCL, 10 random fields were captured using a
Nikon Eclipse 80i microscope (Nikon UK, Kingston Upon Thames). Images were transferred
to a PowerPoint programme where a grid was overlaid on each image. The number of CD68+,
Iba-1+ and CD68+/Iba+ colocalised cells were assessed, allowing for the percentage of microglia
cells that were Iba-1-/CD68+ to be determined.
Semi-quantitative fibrinogen analysis. Fibrinogen staining patterns were also assessed
semi quantitatively in the identified ROI by two independent observers (RW & JRH). This
generated two scores: Firstly, the extent of parenchyma/perivascular staining (S3A Fig) was
assessed as none (G0), perivascular staining only (G1), or immunoreactivity throughout the
WM ROI, intense (I) and less intense (L) respectively (G2I or G2L). Secondly, the overall
fibrinogen immunoreactivity (S3B Fig) was graded as follows; very faint overall immunoreac-
tivity with the odd immunopositive glial cell, axonal/capillary tract with possible perivascular
deposition of fibrinogen (G0). Overall more immunopositive axonal/ capillary tracts alongside
possible perivascular deposition of fibrinogen with fewer immunopositive cells (G1). Overall
more immunopositive cells with fewer immunopositive axonal/capillary tracts alongside possi-
ble perivascular deposition of fibrinogen (G2). Intense cell specific and axonal/capillary tract
immunoreactivity throughout the ROI (G3).
Microglial morphology metric
Microglial phentotype profiles were quantitatively assessed using a metric that considered
both shape and size of the individual cells. We defined the ‘morphology (M) metric’ for quanti-
fying microglial cell morphology along the ‘ramified’ to ‘amoeboid’ spectrum as follows,
Mi ¼
Ci
Ai   A0
A0
; if Ai � A0;
0 if Ai < A0;
8
<
:
where i indexes the cells in the image. Ai is the cell’s total area and A0 is the minimum area
considered for the cells to be analysed. ci is the cell’s roundness which is defined as ci ¼
4pAi
Pi2
,
where Pi is the cell’s perimeter.
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For each sample, we computed the mean score
�M¼
1
N
XN
i¼1
Mi
Where N is the total number of cells with A> A0 in a sample.
The M-score gives a higher value to more larger and rounder structures. An overall thresh-
old area of 500 pixels was set for all three microglia markers Iba-1, CD68 and MHCII. There-
fore, structures whose area was smaller than 500 pixels (26.45 μm^2) have a score equal to zero.
Structures below this threshold were not specific to individual cells, picking out transverse
microglial processes and therefore these were not considered in the overall analysis. As the
structures/cells increase in size (area), so does the metric (Fig 1).
Statistical analysis
Spearman’s rank correlation was used to assess the relationship between the separate histo-
scores from both the Visiopharm and MATLAB toolbox analyses of microglial density. The
relationship between the different markers within the different patient groups was determined
using a non-parametric Kruskal-Wallis test with the Dunn’s multiple comparison test. For
fibrinogen semi-quantitative analysis, interobserver variability was assessed using weighted
kappa and differences between the WM groups were determined using Chi Square. All graphs
and data analysis was completed in GraphPad Prism version 7 (GraphPad Prism In., USA).
Fig 1. Microglial morphology metric. Each positively stained microglial was assigned a M-score, based on the area and roundness of the individual immunopositive
cell. The less round and smaller the cell (more resting, ramified microglia) resulted in a smaller M-score. The more round and larger the cell (more amoeboid,
phagocytic microglia) resulted in a larger M-score.
https://doi.org/10.1371/journal.pone.0210888.g001
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Results
A significant difference in Iba-1 and CD68 immunoreactivity but not
MHCII immunoreactivity is apparent across the three white matter groups
The immunoreactive profile of Iba-1, CD68 and MHCII was assessed across the three groups.
In non-lesional control cases, Iba-1 immunolabelled ramified, bipolar cells throughout the
WM (Fig 2A). This pattern of Iba-1 immunoreactivity was also a feature of NAWM, in addi-
tion to larger cells with retracted cell processes, consistent with the morphology of “primed
microglia” (Fig 2B). Within DSCL a combination of both Iba-1 immunopositive, ramified and
larger amoeboid, round cells were present (Fig 2C). In comparison, there were very few
CD68+ cells in control cases (Fig 2D) with an increase in CD68 immunoreactivity in the
NAWM cases presenting immunopositive cells with retracting processes (Fig 2E), through to
the enlarged, swollen, amoeboid cells present in the DSCL (Fig 2F). CD68 immunoreactivity
within DSCL was prominent in the cell body indicative of a phagocytic microglial phenotype.
MHCII immunoreactivity was scarce in control cases (Fig 2G), with a slight increase in immu-
noreactivity of the typical ramified microglial cell profile within NAWM cases (Fig 2H) with
very little difference in immunoreactivity seen between the NAWM and DSCL cases (Fig 2I).
However, a few MHCII+ amoeboid cells were present amongst the limited number of ramified
MHCII+ cells in the DSCL. For quantitative analysis of each of the different microglial mark-
ers, we compared two different analysis packages; our own system within the MATLAB
toolbox and a Visiopharm application. The packages strongly correlated with each other when
assessing the microglial immunoreactivity (Spearman’s rank CD68 r = 0.920, p = 0.0001; Iba-1
r = 0.926, p = 0.0001; MHCII r = 0.801, p = 0.0001). Henceforth, all results presented in this
paper are from the MATLAB toolbox unless otherwise stated. Both Iba-1 and CD68 staining
differed between control, NAWM and DSCL groups (Fig 3A and 3B) respectively (Kruskal-
Wallis Iba-1; p = 0.0017, CD68; p = 0.0001). However, no difference was seen in MHCII stain-
ing across the three groups (Fig 3C) (Kruskal-Wallis MHCII; p = 0.2010). Quantification of
Iba-1 immunoreactivity showed significantly higher levels of Iba-1 immunoreactivity in
NAWM vs. controls (p = 0.0026) and a significantly reduced expression in DSCL vs. NAWM
(p = 0.0121), Fig 3A. A significant increase in CD68 immunoreactivity was seen in NAWM vs.
controls (p = 0.0011) and in DSCL vs. controls (p<0.0001) with no significant difference in
expression in DSCL vs. NAWM, Fig 3B. When comparing both Iba-1 and CD68 immunoreac-
tivity it is worth noting that the overall total immunoreactive area of CD68 within DSCL
regions was around half of that of Iba-1 within DSCL regions (S4 Fig). In summary, the Iba-1
microglial load was significantly increased in the NAWM group compared to controls and sig-
nificantly decreased in the DSCL group compared to NAWM, to levels comparable to that
seen in controls. In contrast, the CD68 microglial load was significantly increased in both the
NAWM and DSCL groups compared to controls. No significant difference was identified in
the expression of MHCII across the groups (Fig 3C).
The morphology of Iba-1+ and CD68+ but not MHCII+ microglia
significantly varies between the three white matter groups
In each ROI, the shape of microglia along the ‘ramified-amoeboid’ axis was assessed using the
morphology metric (‘M-score’) for each microglial marker (refer to Fig 1). The shape of Iba-
1-labelled microglia differed between the three groups (Kruskal-Wallis Iba-1; p = 0.0001) with
a significantly increased Iba-1 microglia M-score in NAWM vs. control (p = 0.0010) and
DSCL vs. control (p = 0.0001), while no significant difference in the M-score was seen between
DSCL vs. NAWM (Fig 4A).
Microglia and white matter lesions
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The shape of CD68+ microglia differed between the three groups (Kruskal-Wallis CD68;
p = 0.0001) with a significantly increased CD68 microglia M-score in DSCL vs. NAWM
(p = 0.0001) and DSCL vs. control (p = 0.0001). No difference in CD68 microglial M-score
Fig 2. Microglial immunostaining. Iba-1 (A-C), CD68 (D-F) and MHCII (G-I) protein expression within the control, NAWM and DSCL cases. Control WM showed a
regular distribution of Iba-1 positive ramified microglia (A) in contrast to the little CD68 and MHCII immunostaining in control WM (D & G). Within NAWM an
increase in immunoreactivity was evident across all three microglial markers (B,E,H). Within DSCL, Iba-1 and MHCII immunostaining highlighted both ramified and
amoeboid microglia (C & I). In contrast CD68 immunostaining highlighted amoeboid microglia (F). Scale bar = 100μm. NAWM: normal appearing white matter,
DSCL: deep subcortical lesion, WM: white matter, MHCII: major histocompatibility complex II.
https://doi.org/10.1371/journal.pone.0210888.g002
Microglia and white matter lesions
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was observed between the NAWM vs. control cases (Fig 4B). In contrast, there was no signifi-
cant difference identified in the M-score of MHCII+ microglia between the three groups
(Kruskal-Wallis MHCII; p = 0.1890) (Fig 4C).
In summary, the M-score showed significant changes along the ramified to amoeboid axis
from control to NAWM and control to DSCL for Iba-1+ microglia. For CD68+ microglia,
there was an increase in M-Score from control to DSCL and NAWM to DSCL regions, but no
significant increase from control to NAWM. No difference in the M-score was identified for
MHCII+ microglia.
Not all CD68+ microglia express Iba-1
As noted earlier, there appeared to be reduced Iba-1+ but increased CD68+ area fraction in
DSCL compared to NAWM. This seemed counter intuitive given the suggestion that Iba-1 is a
Fig 3. Quantification of microglial cell expression. The immunoreactive mean area of Iba-1 (A), CD68 (B) and MHCII (C) across the cohort. �P<0.05, ��P<0.005
���<0.001 ����P<0.0001. Error bars indicate standard deviation (SD) of the mean. MHCII: major histocompatibility complex II, ns: non-significant.
https://doi.org/10.1371/journal.pone.0210888.g003
Fig 4. Microglial morphology analysis. Iba-1 labelled microglial increase in size and roundness (M-score) throughout the three groups, indicative of an increasing
amoeboid, phagocytic phenotype between DSCL vs NAWM and NAWM vs control cases (A). CD68-labelled microglia also increase in size and roundness, indicative of
amoeboid, phagocytic phenotype between DSCL vs NAWM and control cases (B). MHCII-labelled microglia show no significant difference in their M-score between
the three groups (C). �P<0.05, ��P<0.005 ���<0.001 ����P<0.0001. Error bars indicate standard deviation (SD) of the mean. NAWM: normal appearing white matter,
DSCL: deep subcortical lesion, MHCII: major histocompatibility complex II, ns: non-significant.
https://doi.org/10.1371/journal.pone.0210888.g004
Microglia and white matter lesions
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pan microglial marker. To resolve this, double-labelling IHC was performed. This revealed
that the majority of the large, swollen amoeboid microglia were CD68 immunopositive. While
a number of these CD68 immunopositive cells were also Iba-1+ (Fig 5, red arrow) but others
were Iba-1- (Fig 5, black arrows). This was also confirmed using immunofluorescence (S5 Fig).
In a representative case following quantification, approximately 32.5% of the total microglia in
DSCL were CD68+/Iba-1-. Alongside the amoeboid microglia within the DSCL were the typi-
cal ramified microglia, the majority of which were Iba-1 immunopositive (Fig 5, blue arrows).
Fig 5. Microglial immunohistochemistry. Distinct microglial cell populations are evident within the deep subcortical
lesion (DSCL). CD68+ amoeboid microglial (red) were indicated by the black arrow and separate more ramified cells
were labelled with Iba-1 (brown) indicated by the blue arrow. Dual staining showed some colocalisation of CD68 (red)
and Iba-1 (brown) indicated by the red arrow. Scale bar = 50μm.
https://doi.org/10.1371/journal.pone.0210888.g005
Microglia and white matter lesions
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Thus it appears that in the transition from NAWM to DSCL, there is an increase in the num-
bers of microglia with CD68 expression with a corollary shift from ramified to amoeboid mor-
phology and a contrasting loss of Iba-1 expression.
Myelin integrity is reduced in DSCL compared to control and NAWM
Myelin integrity was assessed by PLP immunostaining which differed significantly between
the control, NAWM and DSCL groups when analysed (Kruskal-Wallis PLP; p<0.0001). PLP
immunostaining was significantly lower in DSCL vs. NAWM (p = 0.0002) and in DSCL vs.
controls (p = 0.0019) (Fig 6A). Both analysis packages (MATLAB toolbox and Visiopharm
application) strongly correlated with each other when assessing the extent of PLP immunore-
activity, Spearman r = 0.8395, p<0.0001. Additionally the expression of PLP negatively corre-
lated with CD68 expression (r = -0.3117, p = 0.0210).
Fig 6. A loss of vascular integrity does not contribute to WM pathology. A decrease in PLP expression in DSCL vs control and DSCL vs NAWM (A).GFAP
immunoreactivity increases in NAWM vs controls (B). No significant differences in AQP4 (C) and fibrinogen (D) are apparent across the cohort. A subtle increase in
Coll IV in NAWM vs control and DSCL vs control was identified (E). �P<0.05, ��P<0.005 ���<0.001 ����P<0.0001. Error bars indicate standard deviation (SD) of the
mean. PLP: proteolipid protein, DSCL: deep subcortical lesion, NAWM: normal appearing white matter, GFAP: glial fibrillary acidic protein, AQP4: aquaporin 4, Coll
IV: collagen IV, ns: non-significant.
https://doi.org/10.1371/journal.pone.0210888.g006
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A loss of vascular integrity does not contribute to microglial changes in the
brain
Given that the expression of the microglia markers Iba-1 and CD68 differ across the lesion
cohort and PLP expression negatively correlates with CD68 immunoreactivity (as PLP expres-
sion decreases the expression of CD68+ microglia increases) it was important to investigate the
potential causes of these changes. Recently it has been suggested changes in vascular integrity
within the brain may cause demyelination and the associated changes in glia that maybe con-
tributing to or preventing DSCL formation. Consequently, we investigated the expression of a
range of vascular markers in our patient cohort including: Coll IV, a marker of vessel basement
membrane; fibrinogen, a serum protein used as a marker of vascular leakiness; and AQP4 a
protein expressed on astrocyte end feet that regulates the transport of water and is believed to
contribute to vascular integrity in the brain. GFAP immunoreactivity was significantly higher
in NAWM vs. control cases (p = 0.0319) (Fig 6B) and correlated with the three microglial
markers across the whole cohort (GFAP vs. Iba-1 r = 0.2644, p = 0.0530, GFAP vs. CD68
r = 0.3208, p = 0.0180, GFAP vs. MHCII r = 0.354, p = 0.0136), AQP4 expression did not
appear to be significantly altered across the groups (Fig 6C). Additionally, we found no signifi-
cant difference in the area density of fibrinogen deposition across the cases investigated (Fig
6D). Similarly, the analyses of the pattern and intensity of fibrinogen deposition did not differ
significantly between groups when rated by either observer (all P� 0.067 by Chi square):
Fibrinogen immunoreactivity was present and varied across the whole cohort (S3 Fig) suggest-
ing serum protein deposition in the ageing brain regardless of WML status. However, there
was a difference in Coll IV immunoreactivity across the patient cohort (Kruskal-Wallis;
p = 0.0030): There was greater Coll IV immunoreactivity in NAWM vs. control (p = 0.0180)
and DSCL vs. control cases (p = 0.0076) (Fig 6E). In summary, while there is initial evidence
for vascular basement membrane changes, evidence of a loss in vascular integrity contributing
to changes in microglial pathology are not apparent.
Discussion
Microglia are diverse cells that express a range of different markers associated with their par-
ticular function and role within the CNS [9]. This current study uses two separate image analy-
sis platforms to quantitate Iba-1, CD68 and MHCII immunoreactivity across control, NAWM
and DSCL of an ageing cohort. While NAWM has greater levels of Iba-1 microglial immuno-
reactivity than control brains, the formation of a DSCL against a background of NAWM
appears to be associated with a loss of Iba-1 immunoreactivity in microglia. This conflicts with
the recurring acceptance in the literature of Iba-1 as a pan microglial marker [13]. On the
other hand, an expected increase in CD68 immunoreactivity was identified with progression
from control, to NAWM to DSCL.
With specific cellular staining associated with all three microglial markers the image analy-
sis carried out by both the MATLAB toolbox and Visiopharm application were highly compa-
rable and generated similar intergroup differences.
Hopperton et al recently reviewed the literature surrounding microglia markers in human
post-mortem brain samples from control subjects and patients with Alzheimer’s disease (AD),
which is known to be associated with WML [21]. The review concluded that of the existing
studies, 76/113 measured microglia using one of the three common markers; Iba-1, CD68, and
MHCII. Consistent upregulation of CD68 and MHCII was identified in AD compared to con-
trol brains. This supports our finding of increased CD68 expression in NAWM and DSCL
regions but contrasts with our finding of no differences of MHCII expression across the three
WM groups. None the less 7/43 studies in the Hopperton et al review also showed no
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difference in MHCII expression between AD and control across multiple brain regions. It
should be noted that the population-based design of CFAS contrasts with the Hopperton et al
meta-analysis, which drew studies that focussed on AD. Thus raising the possibility that the
relationship of MHCII with WML may vary as a function of Alzheimer pathology. Of the 20
studies that compared Iba-1, 10 studies showed no difference or a decrease in Iba-1 in AD rela-
tive to control brains coinciding with our finding of relatively similar levels of Iba-1 in the
DSCL of an ageing cohort compared to control cases. It would thus appear that a loss of micro-
glial Iba-1 is associated with pathological, neurodegenerative states.
Iba-1, a cytoplasmic protein that reflects microglial motility and migration, is widely
regarded as a pan-microglial marker [13, 14, 22]. In the current study, the total Iba-1 immuno-
reactive area increases in NAWM regions surrounding DSCLs compared to control regions,
but decreases in the transition from NAWM to DSCL. This may imply increased migration of
microglia as a ‘field change’ in NAWM from brains with DSCL, followed by a loss of motility
and migration that correlates with DSCL formation.
Whether these Iba-1- microglia are adopting a neurotoxic or neuroprotective phenotype is
unknown. Future work to determine the M1/M2 phenotype of these cells is required. How-
ever, it is known that as the microglia adapt a phagocytic phenotype, they increase in size and
roundness. This has been documented in NAWM where subtle pathological changes occur
including gliosis, myelin and axonal changes etc. [12, 23, 24]. Thus, it is interesting that our
morphology index which assesses size and shape (with higher scores corresponding to larger,
less ramified, more rounded forms) of the Iba-1+ microglia shows stepwise increases through-
out the tissue groups. This, together with the increasing CD68 immunoreactivity suggests the
increasing phagocytic phenotype of microglia from control, NAWM through to DSCL. Our
histological results show that Iba-1 immunolabels two distinct populations of microglia: those
with a ramified profile present in high numbers in the NAWM and as well as phagocytic
microglia, a prominent feature of the DSCL and that are a very prominent feature of CD68+
microglia.
We recognise that cell morphology alone only provides a partial insight into microglial
function and that assessment of the expression of additional microglial markers is crucial to
fully characterise microglial phenotype [10]. However, we maintain, on the basis of our results,
that combining the morphological status of the cells with assessment of marker expression
improves understanding of the microglial function.
The increase in the size and roundness of CD68+ cells from NAWM to DSCL regions is an
additional indication of their phagocytic phenotype. This finding replicates previous studies
that have demonstrated amoeboid CD68+ microglia as a prominent feature in DSCL [7].
Whether the amoeboid phagocytic microglia are causing harm by actively phagocytosing func-
tioning cells, or clearing up debris from damaged axons and degraded myelin therefore
responding to neurodegeneration is open to question [10].
When comparing both Iba-1 and CD68 immunoreactivity it is worth noting that the overall
total immunoreactive area of CD68 within DSCL regions was around half of that of Iba-1.
Therefore, the question rises as to what microglial populations account for the overall Iba-1+/
CD68- immunoreactive area. Comparison of the shape metrics of the Iba-1 and CD68 immu-
nopositive cells, indicates there are greater numbers of CD68+ cells with the larger/less rami-
fied morphology than is seen for Iba-1+ microglia. Consequently, the remaining Iba-1+/CD68-
cells within the DSCL must be of the more ramified, bipolar phenotype. These differences in
CD68 and Iba-1 shape metrics further support our finding that not all CD68+ cells are Iba-1+,
despite the general consensus that Iba-1 is a pan-marker of microglia.
Whether Iba-1 expression loss by CD68+ cells is a feature that is specific to DSCL in ageing
or a phenomenon of WML in general is currently unknown. However, this hypothesis has
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recently been supported by work looking at the relationship between microglial immunopheno-
type in dementia in the context of Alzheimer’s pathology [10]. This study concluded that the
presence of dementia correlated positively with CD68 levels but negatively with Iba-1 levels,
and that different microglial populations may coexist within the brain. Whether the microglia
in the DSCL are a new type of cell that are Iba-/CD68+ arising as a result of the lesion formation
or whether the microglia lose their Iba-1 expression as a result of lesion formation requires
additional testing and examination in other disease processes in a quantitative manner.
The association of WM pathology with BBB dysfunction has been assessed previously
through the detection of serum proteins including fibrinogen, IgG and albumin outside the
vasculature in the brain parenchyma [3, 25]. In the current study, large inter individual differ-
ences in extravascular fibrinogen expression were apparent and there was clear evidence for
serum accumulation in the ageing WM, yet there was no relationship between these index of
BBB dysfunction and WM pathology. The literature to date on this matter is conflicting–some
studies find evidence for serum protein accumulation in the brain, while others do not [26–
28].
Our work showed no apparent differences in AQP4 expression across the cases. This find-
ing suggests no evident change in astrocytic water transport out of the interstitium. This find-
ing is in line with our lack of evidence of vascular leakiness as indexed by fibrinogen IHC
described above. Chen et al have demonstrated that there is loss of AQP4 in astrocytic end-feet
in WML of post stroke patients with dementia compared to the WML of post stroke patients
without dementia [29]. Therefore, future studies could focus on whether AQP4 expression dif-
ferentiates between demented and non-demented patients with DSCL. However, we lack the
sample size and case numbers to test this hypothesis here.
We have demonstrated increased levels of Coll IV immunoreactivity in both NAWM and
DSCL compared to control regions. An increase in Coll IV could be due to a number of fac-
tors, namely an increase in basement membrane thickness or an increase in the number of ves-
sels. Increased basement membrane thickness has been suggested to serve as a protective
measure to prevent vascular leakiness and consequently fibrinogen and other serum protein
deposition and accumulation [30]. Furthermore, an increase in vessel thickness may impede
cerebral blood flow contributing to WML development [31]. Secondly, the increase in Coll IV
could be due to the increased number of vessels in the NAWM and DSCL over the controls as
a result of pathology. Alternatively, the demyelinating lesions could result in ‘compacting’,
reducing intervessel distance and subsequently increasing Coll IV immunoreactivity within
the DSCL. Evidence has shown the tortuosity (lengthening) of arterioles in the deep WM in
areas where brain parenchyma has been lost, particularly in the aged brain [32, 33]. The nature
of the Coll IV alterations, including the possibilities of greater basement membrane thickness
or numbers of blood vessels is currently being investigated by our laboratory.
Conclusions
In summary, this study identifies that some, but not all, microglia markers correlate with the
progression from control WM in the ageing brain to NAWM to fully-developed DSCL. Clearly
when using IHC to investigate the proposed function of particular cell types in pathology it is
important to look at a range of cellular markers. Initially, with progression from control to
NAWM, there is an increase in both CD68+ and Iba-1+ microglia. Following this, with the step
from NAWM to DSCL, there is a further increase in the CD68+ signal. However, uniquely the
study also shows a distinct population of microglia within DSCL that lose their Iba-1 expres-
sion. This finding disputes the existing concept that Iba-1 is a pan-microglial marker. Identify-
ing sub populations of microglia that differ based on the markers they express may ultimately
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help us to decipher their overall function and explain the underlying pathology of neurological
diseases. Therefore, it is important this discovery is explored beyond that of the DSCL in the
ageing brain to investigate whether this finding is apparent in all WML and other neurological
diseases.
Supporting information
S1 Fig. Visiopharm vs MATLAB analysis. The ROI in each case was identified based on the
extent of microglial activation (Iba-1 reactivity and/or CD68 reactivity). The ROI identified in
a NAWM case using Iba-1 immunoreactivity in visiopharm (A). The circular ROI was
depicted in the equivalent MATLAB processed image. The ROI identified from the central
point (red cross) guided by the visiopharm Iba-1 defined ROI (B). The equivalent ROI repre-
sented on the fibrinogen labelled section for the same NAWM case in visiopharm (C). The cir-
cular ROI in the equivalent MATLAB processed fibrinogen image. The ROI was identified
from the central point (red cross) guided from the visiopharm fibrinogen defined ROI (D).
ROI: region of interest, NAWM: normal appearing white matter.
(TIF)
S2 Fig. Visiopharm analysis. An example image uploaded into visiopharm (A) and the main
region of interest (ROI) drawn onto the section (B, green box). The overall mean area of
immunostaining was calculated across the 5 sub ROIs within the main ROI (C).
(TIF)
S3 Fig. Semi-quantitative analysis of fibrinogen. The parenchyma fibrinogen immunoreac-
tivity was graded as G0; absent parenchyma immunoreactivity, G1; perivascular immunoreac-
tivity only, G2L or G2I (Less intense and Intense immunoreactivity); throughout the all
parenchyma. Scale bar = 1mm (A). The pattern of fibrinogen immunoreactivity in the region
of interest (ROI) was graded as G0; very faint immunoreactivity throughout the ROI, G1;
more axonal/capillary immunoreactivity throughout the ROI (black arrows), G2; more cell
specific immunoreactivity throughout the ROI (red arrows), G3; Intense axonal/capillary
(black arrows) and cell specific staining (red arrows) throughout the ROI (B). Parenchyma
staining showed fair agreement between scorers (κ = 0.31) while the overall white matter stain-
ing showed moderate agreement between scorers (κ = 0.59) Scale bar = 100μm.
(TIF)
S4 Fig. Comparison of CD68 and Iba-1 immunoreactivity. The extent of Iba-1 and CD68
immunoreactivity across areas of control, NAWM and DSCL (A). Iba-1 and CD68 microglia
M-score across areas of control, NAWM and DSCL, the higher the M-score the more larger
and rounder the cell (B). Error bars indicate standard deviation (SD) of the mean. NAWM:
normal appearing white matter, DSCL: deep subcortical lesion.
(TIF)
S5 Fig. Microglial double labelling. CD68+ (A, red fluorescent label) and Iba-1 detected with
3,3’-diaminobenzidine (DAB) visualised under light microscopy (B, brown). Double labelling
confirms colocalisation of CD68 and Iba-1 double-labelled cells (C, green arrows) but also
shows a distinct population of Iba-1- cells (B, black arrows) that are CD68+ (C, white arrows)
confirming not all CD68+ cells are Iba-1+. Scale bar = 50μm.
(TIF)
S1 Table. Minimal data set. Visiopharm and MATLAB generated data (MHCII, CD68, Iba-1,
AQP4, Fibrinogen and PLP).
(XLSX)
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